AUTHORS
Cristina Panaroni, PhD, Keertik Fulzele, PhD2, Advait Joshi, MBBS3, Rie Matsubara, MD, PhD4, Allison Maebius, MSc5, Chukwuamaka Onyewadume6, Noopur Raje, MD7
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
6 Massachusetts General Hospital, Boston, Massachusetts, United States
7 Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Osteolineage cells function as versatile regulators of the bone marrow (BM) microenvironment, maintaining hematopoietic stem cell quiescence and orchestrating lineage commitments. Multiple myeloma (MM) cells inhibit bone-forming osteoblasts, partly via DKK-1 secretion, while simultaneously activating bone-resorbing osteoclasts by modulating RANKL/OPG ratio. This decoupling culminates in the hallmark osteolytic myeloma bone lesions. While MM cells actively engineer their BM tumor microenvironment (TME) to foster survival, proliferation, and drug resistance, the consequences of osteoblast loss remain incompletely characterized. Our prior work showed that inhibiting Activin A signaling boosted osteoblast counts and suppressed MM growth in immunodeficient mice injected with MM cells, suggesting that osteoblasts contribute to myeloma pathogenesis. Here, we hypothesized that the loss of osteoblasts promotes MM progression by modulating BM TME.
We generated an immunocompetent mouse model for inducible, reversible postnatal deletion of mature osteoblasts by mating homozygous iDTR-floxed mice with heterozygous osteocalcin-promoter-driven Cre (OC-Cre/iDTR) mice. Cre-negative iDTR littermates served as controls. OC-Cre/iDTR mice were phenotypically normal before diphtheria toxin (DT) treatment, with no baseline differences in immune populations or skeletal architecture as assessed by flow cytometry or micro-computed tomography (micro-CT), respectively. 5TGM1 MM cells engineered to express luciferase/tdTomato (5TGM1-Luc-Tom) enabled non-invasive bioluminescence imaging (BLI) of tumor burden. At skeletal maturity (8 weeks of age), osteoblast deletion was induced in OC-Cre/iDTR mice by i.p. DT (25-50 μg/kg) injections. Within one-week, micro-CT evaluations revealed a significant increase in cortical porosity. Following 8 weeks of DT administration, OC-Cre/iDTR mice showed significant reductions in trabecular bone volume fraction (BV/TV), trabecular number (Tb.N), and bone mineral density (BMD), along with significantly increased trabecular spacing (Tb.Sp). Osteocalcin immunohistochemistry confirmed the rapid, targeted loss of mature endosteal osteoblasts (N.Ob/T.Ar), which matched the sharp declines in serum osteocalcin and sclerostin. Importantly, osteoclast parameters (N.Oc/T.Ar and serum CTX) remained unchanged.
To analyze MM engraftment and progression kinetics, 1×106 5TGM1-Luc-Tom cells were injected into the left tibia one-week post-DT initiation and followed for up to 8 weeks. Flow cytometry revealed a 4-fold increase in 5TGM1-Luc/tdTom cells in the BM of OC-Cre/iDTR mice versus controls. At 4 weeks, bioluminescence imaging showed a 600-fold greater tumor burden in OC-Cre/iDTR mice. Notably, by 8 weeks, BLI detected dissemination of MM cells to other long bones only in OC-Cre/iDTR mice.
To determine the mechanistic drivers of MM proliferation in the absence of mature osteoblasts, a multiplex biochemical assay measuring 200 distinct cytokines and growth factors in BM extracellular fluid was performed. The OC-Cre/iDTR mice showed significantly altered expression levels of immunoregulatory cytokines that are classically associated with an immunosuppressive environment, notably Interleukin-33 (IL-33), IL-4, IL-13, and CCL-2. ELISA, IHC, and qPCR analysis confirmed significantly increased levels of IL-33, IL-4, and IL-13 in the BM TME of OC-Cre/iDTR mice compared to controls. Multiparametric flow cytometry analysis of the total BM extracted from the 5TGM1-injected tibias showed significant expansion of CD4+/CD25+/FoxP3+ regulatory T-cells (Tregs) and granulocytic/monocytic myeloid-derived suppressor cells (MDSCs) when compared to the immune landscape of the iDTR controls.
These findings establish that the postnatal deletion of mature osteoblasts actively converts the BM TME into an IL-33-enriched, highly immunosuppressive niche that facilitates rapid MM engraftment, accelerated proliferation, and systemic metastasis. IL-33 exerts its pleiotropic effects through its receptor, Suppression of Tumorigenicity 2 (ST2), also designated IL-1RL1. Intercepting the IL-33/ST2 signaling axis or restoring the mature osteoblastic niche represents a promising therapeutic strategy to reverse BM immune escape and achieve long-term tumor control. This immunocompetent model serves as an essential platform for dissecting the complex osteo-immune cross-talk driving myeloma pathogenesis.
DISCLOSURES
Cristina Panaroni, PhD: No relevant conflicts of interest to declare.